Endocrine Pharmacology Practice Questions

Q: What is the mechanism of action of finasteride?

5-alpha reductase inhibition. ***5-alpha reductase inhibition*** - Finasteride inhibits the **Type II 5-alpha reductase enzyme**, which is responsible for converting **testosterone** to the more potent **dihydrotestosterone (DHT)**. - By reducing intraprostatic DHT levels, it leads to a decrease in **prostate volume** and improves symptoms of **Benign Prostatic Hyperplasia (BPH)**. *Adrenergic α1A receptor antagonism* - This mechanism is characteristic of **alpha-blockers** like **tamsulosin**, not finasteride. - Alpha-blockers work by relaxing the **smooth muscle** of the prostate and bladder neck, providing immediate symptom relief by reducing **dynamic obstruction**. *Androgen receptor blockade* - This describes drugs like **flutamide** or **bicalutamide**, which compete with androgens for binding sites on **androgen receptors**. - These are typically used for **prostate cancer** management rather than for treating BPH symptoms via enzyme inhibition. *Phosphodiesterase inhibition* - This mechanism applies to **phosphodiesterase-5 (PDE5) inhibitors** like **sildenafil** or **tadalafil** used for erectile dysfunction or pulmonary hypertension. - While tadalafil is sometimes used in BPH, it works by increasing **cyclic GMP** levels to cause smooth muscle relaxation, not by affecting hormonal pathways.

Q: What is the mechanism of action of Resmetirom?

Stimulation of Thyroid Hormone Receptor-beta. ***Stimulation of Thyroid Hormone Receptor-beta*** - Resmetirom is a first-in-class, oral, liver-directed **selective thyroid hormone receptor-beta (THR-β) agonist**. - By stimulating this receptor specifically in the liver, it helps reduce **hepatic lipotoxicity**, downregulate **fibrogenesis**, and improve lipid metabolism, making it indicated for **non-alcoholic steatohepatitis (NASH)** with liver fibrosis. *Blockage at NPC1L1 transporter* - This mechanism describes **Ezetimibe**, a drug used to treat **hypercholesterolemia** by inhibiting cholesterol absorption in the small intestine. - It does not target liver fibrosis or NASH directly through thyroid hormone pathways. *Activation of PPAR-γ* - This is the mechanism of **Thiazolidinediones** (e.g., Pioglitazone), which are insulin-sensitizing agents. - While used in diabetes and sometimes studied in NASH, they work by enhancing insulin sensitivity rather than selectively agonizing hepatic THR-β. *Blockage of Acetyl Co-A carboxylase* - Inhibitors of acetyl-CoA carboxylase (ACC), such as Firsocostat, were investigated for NASH to reduce **de novo lipogenesis**. - They function by inhibiting the rate-limiting step in fatty acid synthesis, distinct from thyroid receptor modulation.

Q: A 45-year-old woman presents with heat intolerance, palpitations, and weight loss despite increased appetite. Physical examination reveals a diffusely enlarged thyroid gland, warm moist skin, and fine tremor. Laboratory tests show TSH <0.01 mIU/L (normal 0.5-5.0), free T4 4.5 ng/dL (normal 0.9-1.7), and positive TSH receptor antibodies. She is started on methimazole. Apply your knowledge of thyroid physiology to explain the mechanism by which this medication will restore euthyroid state.

Inhibits thyroid peroxidase-mediated iodination of thyroglobulin. ***Inhibits thyroid peroxidase-mediated iodination of thyroglobulin*** - **Methimazole** belongs to the thionamide class and works by inhibiting the enzyme **thyroid peroxidase (TPO)**. - This action prevents the **organification** of iodide and the **coupling** of iodotyrosines, effectively halting the synthesis of new thyroid hormones. *Blocks iodide uptake by inhibiting the sodium-iodide symporter* - This mechanism is characteristic of **anion inhibitors** like **perchlorate** or thiocyanate. - **Methimazole** does not interfere with the active transport of iodide into the thyroid follicular cell. *Enhances hepatic metabolism of circulating thyroid hormones* - No first-line antithyroid medications work by increasing the **hepatic clearance** or metabolism of T3/T4. - Management of hyperthyroidism focuses on decreasing **hormone production** or blocking peripheral effects rather than metabolic destruction. *Increases peripheral conversion of T4 to reverse T3* - While **Propylthiouracil (PTU)** inhibits the peripheral conversion of T4 to active T3, **methimazole** lacks this specific peripheral inhibitory effect. - Increasing **reverse T3** is not a primary therapeutic goal or a mechanism of action for methimazole. *Competitively blocks TSH receptors on thyroid follicular cells* - Methimazole does not act as a **receptor antagonist**; it acts intracellularly on the biosynthetic pathway. - In **Graves' disease**, TSH receptor antibodies (TRAb) stimulate the receptor, but methimazole reduces the resulting **hormone output** instead of blocking the antibody-receptor binding.

Q: What is the mechanism by which GnRH analogs achieve pubertal suppression when used continuously in gender dysphoria management?

Down-regulation of pituitary GnRH receptors leading to decreased gonadotropin release. ***Down-regulation of pituitary GnRH receptors leading to decreased gonadotropin release*** - Continuous (non-pulsatile) administration of **GnRH analogs** leads to the **desensitization** and down-regulation of GnRH receptors on pituitary **gonadotrophs**. - This process inhibits the release of **LH and FSH**, resulting in the suppression of gonadal sex steroids to prepubertal levels, which halts **pubertal progression**. *Direct inhibition of gonadal steroidogenesis* - These drugs primarily act on the **anterior pituitary gland** rather than directly on the enzymatic pathways within the gonads. - The drop in steroid levels is a **secondary effect** of the lack of trophic stimulation from **gonadotropins**. *Competitive inhibition of GnRH receptors* - This refers to the mechanism of **GnRH antagonists** (e.g., Cetrorelix), which block receptors immediately without an initial flare. - **GnRH analogs** (agonists) first activate the receptor before causing the regulatory **down-regulation** that leads to suppression. *Upregulation of sex hormone-binding globulin* - While changes in **SHBG** can alter the levels of free hormones, it is not the primary mechanism of action for **pubertal blockers**. - The goal of GnRH analog therapy is to stop the **production** of sex hormones, not just manage their transport in the bloodstream.

Q: Why is spironolactone commonly used as an anti-androgen in transgender women undergoing feminizing hormone therapy?

It blocks androgen receptors and inhibits 5-alpha reductase. ***It blocks androgen receptors and inhibits 5-alpha reductase*** - **Spironolactone** acts primarily by **competitively blocking androgen receptors**, preventing testosterone and DHT from exerting their biological effects. - It also exhibits secondary activity by **inhibiting 5-alpha reductase**, the enzyme responsible for converting testosterone into the more potent **dihydrotestosterone (DHT)**. *It stimulates SHBG production* - **Sex Hormone-Binding Globulin (SHBG)** levels are typically increased by **oral estrogens**, not directly by spironolactone. - While higher SHBG levels decrease free testosterone, this is not the **primary mechanism** of action for spironolactone's anti-androgenic effects. *It increases estrogen receptor sensitivity* - Spironolactone does not have a known mechanism for increasing the **sensitivity or density** of estrogen receptors. - Its feminizing effects in hormone therapy are indirect, achieved by **reducing the interference** of male sex hormones at the cellular level. *It directly inhibits testosterone synthesis* - While spironolactone may have minor inhibitory effects on **17α-hydroxylase** and **17,20-desmolase**, its primary clinical efficacy is as a **receptor antagonist**. - Potent inhibition of synthesis is more characteristic of **GnRH agonists** or medications like ketoconazole, rather than the primary goal of spironolactone use.

Q: Which drug class is known to cause osteoporosis on long-term use?

GnRH analogues. ### Explanation **Correct Option: C. GnRH analogues** The correct answer is **GnRH analogues** (e.g., Leuprolide, Goserelin). When administered continuously, these drugs cause down-regulation and desensitization of GnRH receptors in the pituitary gland. This leads to a profound suppression of FSH and LH, resulting in a state of **hypogonadotropic hypogonadism**. Since estrogen and testosterone are essential for maintaining bone mineral density (BMD) by inhibiting osteoclast activity, their chronic suppression leads to accelerated bone resorption and **osteoporosis**. **Analysis of Incorrect Options:** * **A. Estrogen:** Estrogen is actually **bone-protective**. It inhibits RANK-L signaling and induces osteoclast apoptosis. It is used in HRT to prevent postmenopausal osteoporosis. * **B. Progesterone:** Progestins generally have a neutral or slightly protective effect on bone. However, high-dose Medroxyprogesterone acetate (DMPA) can cause transient bone loss, but it is not the classic "textbook" cause compared to GnRH analogues. * **D. Warfarin:** While some studies suggest Warfarin interferes with Vitamin K-dependent bone proteins (like osteocalcin), it is not a primary or high-yield cause of osteoporosis in clinical exams. **Heparin** is the anticoagulant classically associated with osteoporosis. **High-Yield Clinical Pearls for NEET-PG:** * **Other drugs causing osteoporosis:** Glucocorticoids (most common cause), Heparin (long-term), Phenytoin, Proton Pump Inhibitors (PPIs), and Aromatase Inhibitors (e.g., Anastrozole). * **Add-back therapy:** To prevent bone loss during long-term GnRH analogue use (e.g., for endometriosis or fibroids), low-dose estrogen/progestin is often co-administered. * **GnRH Pulsatility:** Remember, **pulsatile** GnRH stimulates ovulation, while **continuous** GnRH suppresses the axis.

Q: Which antidiabetic drug has an anorectic effect?

Liraglutide. **Explanation:** **Liraglutide** is the correct answer because it is a **GLP-1 (Glucagon-Like Peptide-1) receptor agonist**. These drugs exert an anorectic effect through two primary mechanisms: 1. **Central Action:** They act on the hypothalamus to increase satiety and decrease appetite. 2. **Peripheral Action:** They delay gastric emptying, leading to a prolonged feeling of fullness (postprandial satiety). Due to these effects, Liraglutide is specifically FDA-approved for chronic weight management in addition to Type 2 Diabetes. **Analysis of Incorrect Options:** * **Gliclazide & Chlorpropamide:** These are **Sulfonylureas**. They stimulate insulin release from the pancreas. Since insulin is an anabolic hormone, sulfonylureas are notorious for causing **weight gain**, not weight loss. * **Acarbose:** This is an **Alpha-glucosidase inhibitor**. It works locally in the gut to delay carbohydrate absorption. While it is "weight neutral," it does not possess a direct anorectic (appetite-suppressant) effect. **High-Yield Clinical Pearls for NEET-PG:** * **Weight Loss Drugs:** GLP-1 agonists (Liraglutide, Semaglutide) and SGLT-2 inhibitors (Dapagliflozin) are the preferred antidiabetics for obese patients. * **Weight Gain Drugs:** Sulfonylureas, Meglitinides, Insulin, and Thiazolidinediones (Pioglitazone). * **Black Box Warning:** Liraglutide is contraindicated in patients with a personal or family history of **Medullary Thyroid Carcinoma** or Multiple Endocrine Neoplasia type 2 (MEN 2). * **Side Effects:** The most common side effects are GI-related (nausea/vomiting) and a potential risk of pancreatitis.

Q: All of the following are tocolytics except?

Misoprostol. ### Explanation The core concept tested here is the pharmacological management of uterine contractions. **Tocolytics** are drugs used to inhibit uterine contractions (uterine relaxants) to delay preterm labor, whereas **Uterotonics** are drugs used to stimulate contractions. **Why Misoprostol is the correct answer:** **Misoprostol** is a synthetic Prostaglandin E1 (PGE1) analogue. It acts as a potent **uterotonic**, causing cervical ripening and uterine contractions. Clinically, it is used for medical abortion, induction of labor, and the prevention/treatment of Postpartum Hemorrhage (PPH). Because it stimulates rather than inhibits contractions, it is not a tocolytic. **Analysis of Incorrect Options (Tocolytics):** * **Ritodrine & Salbutamol (Options A & B):** These are **Beta-2 ($\beta_2$) adrenergic agonists**. They increase intracellular cAMP, which leads to the relaxation of the myometrial smooth muscle. Ritodrine was historically the only FDA-approved drug for tocolysis, though its use has declined due to maternal side effects like tachycardia and pulmonary edema. * **Isoxsuprine (Option C):** Another $\beta$-adrenergic agonist commonly used in clinical practice as a uterine relaxant to manage threatened abortion and preterm labor. **NEET-PG High-Yield Pearls:** 1. **First-line Tocolytic:** Currently, **Nifedipine** (Calcium Channel Blocker) is preferred due to its efficacy and better side-effect profile. 2. **Atosiban:** A specific **Oxytocin receptor antagonist** used as a tocolytic with the fewest maternal side effects. 3. **Magnesium Sulfate ($MgSO_4$):** Used for **neuroprotection** of the fetus in preterm labor (before 32 weeks) rather than primary tocolysis. 4. **Indomethacin:** A COX inhibitor used for tocolysis, but contraindicated after 32 weeks due to the risk of premature closure of the *ductus arteriosus*.

Q: Women receiving estrogen therapy have an increased risk of development of all of the following EXCEPT:

Carcinoma of the gall bladder. **Explanation:** The question asks for the condition **not** associated with an increased risk from estrogen therapy. While estrogen significantly impacts the hepatobiliary system, it is not a direct carcinogen for the gallbladder. **1. Why "Carcinoma of the Gallbladder" is the correct answer:** Estrogen increases the risk of **cholelithiasis** (gallstones) by increasing cholesterol secretion into bile and decreasing gallbladder motility. While gallstones are a major risk factor for gallbladder cancer, estrogen therapy itself has not been proven to be a direct independent risk factor for the development of gallbladder carcinoma. **2. Analysis of Incorrect Options:** * **Breast Cancer:** Long-term combined Hormone Replacement Therapy (HRT) is a well-established risk factor for breast cancer. Estrogen promotes the proliferation of mammary epithelial cells. * **Endometrial Cancer:** Unopposed estrogen therapy leads to endometrial hyperplasia, which is a precursor to endometrial adenocarcinoma. This is why progesterone is always added for women with an intact uterus. * **Hepatocellular Carcinoma (HCC):** Estrogen is associated with various liver tumors. While more strongly linked to **Hepatic Adenomas**, long-term use of high-dose estrogens (historically in OCPs) has been linked to an increased risk of HCC. **Clinical Pearls for NEET-PG:** * **Protective Effect:** Estrogen therapy (specifically OCPs) significantly **decreases** the risk of Ovarian and Endometrial cancers. * **The "Rule of Threes":** Estrogen increases the risk of three "stones/clots": Gallstones, Kidney stones (minor association), and Thromboembolism (DVT/PE). * **Contraindication:** A history of undiagnosed vaginal bleeding or estrogen-dependent tumors is an absolute contraindication for estrogen therapy.

Question 1

What is the mechanism of action of finasteride?

Accepted Answer

5-alpha reductase inhibition

Answer

Adrenergic α1A receptor antagonism

Answer

Androgen receptor blockade

Answer

Phosphodiesterase inhibition

Question 2

What is the mechanism of action of Resmetirom?

Accepted Answer

Stimulation of Thyroid Hormone Receptor-beta

Answer

Blockage at NPC1L1 transporter

Answer

Activation of PPAR-γ

Answer

Blockage of Acetyl Co-A carboxylase

Question 3

A 62-year-old man with type 2 diabetes mellitus presents for routine follow-up. His HbA1c is 8.2% despite metformin and lifestyle modifications. His physician considers adding a GLP-1 receptor agonist. Apply physiological principles to predict the expected effects of this medication on his glucose homeostasis.

Accepted Answer

Glucose-dependent insulin secretion, decreased glucagon, and delayed gastric emptying

Answer

Inhibition of renal glucose reabsorption at the proximal tubule

Answer

Increased insulin secretion independent of glucose levels with decreased glucagon

Answer

Direct stimulation of peripheral glucose uptake via GLUT4 translocation

Answer

Enhanced hepatic glucose uptake through GLUT2 upregulation

Question 4

A 45-year-old woman presents with heat intolerance, palpitations, and weight loss despite increased appetite. Physical examination reveals a diffusely enlarged thyroid gland, warm moist skin, and fine tremor. Laboratory tests show TSH <0.01 mIU/L (normal 0.5-5.0), free T4 4.5 ng/dL (normal 0.9-1.7), and positive TSH receptor antibodies. She is started on methimazole. Apply your knowledge of thyroid physiology to explain the mechanism by which this medication will restore euthyroid state.

Accepted Answer

Inhibits thyroid peroxidase-mediated iodination of thyroglobulin

Answer

Blocks iodide uptake by inhibiting the sodium-iodide symporter

Answer

Enhances hepatic metabolism of circulating thyroid hormones

Answer

Increases peripheral conversion of T4 to reverse T3

Answer

Competitively blocks TSH receptors on thyroid follicular cells

Question 5

What is the mechanism by which GnRH analogs achieve pubertal suppression when used continuously in gender dysphoria management?

Accepted Answer

Down-regulation of pituitary GnRH receptors leading to decreased gonadotropin release

Answer

Direct inhibition of gonadal steroidogenesis

Answer

Competitive inhibition of GnRH receptors

Answer

Upregulation of sex hormone-binding globulin

Question 6

Why is spironolactone commonly used as an anti-androgen in transgender women undergoing feminizing hormone therapy?

Accepted Answer

It blocks androgen receptors and inhibits 5-alpha reductase

Answer

It stimulates SHBG production

Answer

It increases estrogen receptor sensitivity

Answer

It directly inhibits testosterone synthesis

Question 7

Which drug class is known to cause osteoporosis on long-term use?

Accepted Answer

GnRH analogues

Answer

Estrogen

Answer

Progesterone

Answer

Warfarin

Question 8

Which antidiabetic drug has an anorectic effect?

Accepted Answer

Liraglutide

Answer

Gliclazide

Answer

Acarbose

Answer

Chlorpropamide

Question 9

All of the following are tocolytics except?

Accepted Answer

Misoprostol

Answer

Ritodrine

Answer

Salbutamol

Answer

Isoxsuprine

Question 10

Women receiving estrogen therapy have an increased risk of development of all of the following EXCEPT:

Accepted Answer

Carcinoma of the gall bladder

Answer

Breast cancer

Answer

Endometrial cancer

Answer

Hepatocellular carcinoma

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?